Category: Press Release

2025.01.08

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

2025.01.06

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

2024.11.21

I-Mab to Participate at the Piper Sandler Healthcare Conference

2024.11.14

I-Mab Reports Third Quarter 2024 Results

2024.11.06

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

2024.10.31

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

2024.10.30

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

2024.10.28

I-Mab to Participate at the Truist Securities BioPharma Symposium

2024.09.16

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

2024.09.10

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer